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A B S T R A C T
Background: Although HPV-positive oropharyngeal cancer (OPC) patients have improved prognosis compared to
HPV negative patients; there remains an HPV-positive group who have poor outcomes. Biomarkers to stratify
discrete patient outcomes are thus desirable. Our objective was to analyse viral load (VL) by droplet digital PCR
(ddPCR), in HPV-positive patients with OPC on whom clinical outcome data were available.
Methods: In a cohort of patients that had previously tested HPV positive via conventional PCR, VL was de-
termined using ddPCR assays for HPV16 L1 and E6 genes. VL was classed as “medium/high” if more than 5.57
copies or 8.68 copies of the HPV 16 L1 or E6 gene were detected respectively. Effect of VL on overall survival and
hazard of death & disease progression was performed with adjustments made for sex, age, deprivation, smoking,
alcohol consumption and stage.
Results: L1 VL ranged from 0.0014–304 gene copies per cell with a mean of 30.9; comparatively E6 VL ranged
from 0.0012–356 copies per cell with a mean of 37.9. Univariate analysis showed those with a medium/high VL
had a lower hazard of death; this was significant for L1 (p=0.02) but not for E6 (p= 0.67). The ratio of E6 to L1
deviated from n=1 in most samples but had no influence on clinical outcomes.
Conclusions: HPV viral load may be informative for the further stratification of clinical outcomes in HPV positive
OPC patients
1. Introduction
The incidence of oropharyngeal cancer (OPC) has increased dra-
matically over the last two decades including in the United Kingdom
[1,2]. A component of OPC is associated with HPV although the amount
varies. For example, a recent global analysis indicated<10 % of OPC
cases in Brazil were positive for HPV compared to∼50 % in the UK [3].
While the extent of HPV driven OPC varies, data converge on the fact
that HPV positive (versus negative) status is independently associated
with better clinical outcomes [4,5]. This has led to a recent change in
tumour classification which incorporates HPV status and also trials to
determine the efficacy of de-escalated therapy in HPV positive OPC
patients [6,7].
Current approaches for determining HPV status of OPC are largely
based on qualitative tests and include immunohistochemistry for
p16INK4a or HPV PCR for DNA or mRNA [8]. Unfortunately, some
HPV-positive patients, so determined by these methods, still have very
poor outcomes [9]. Further, these approaches do not quantify levels of
infection i.e. viral load (VL). Given the increased incidence of OPC, it is
important to refine tools for improved risk stratification; one such
candidate is the measurement of viral load.
Current evidence indicates that VL in HPV-positive head and neck
cancers varies widely within and between anatomical sites [10–14]. In
addition, investigations into the physical status of HPV in OPC indicate
a landscape of integrated and episomal forms within a single lesion
[15,16]. The implications of physical status on clinical outcome are not
understood but given the fundamental influence of integration on viral
gene expression, a simple measure of virus activity (such as VL in the
lesion) may yield insight into clinical manifestations.
To date, small cohort studies have indicated VL measurement can
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delineate patient outcomes within HPV positive OPC [17]. This re-
conciles with data that indicate VL may be prognostic for other HPV
driven cancers, including cervix [18,19]. Previous studies on VL have
generally focussed on the amplification of one target and have em-
ployed real-time PCR. ddPCR allows absolute quantification of DNA
targets and has been used for applied virology where knowledge of load
can influence clinical management [20,21]. Around 20,000 data points
are generated per sample making it highly accurate and reproducible
(2021) and proof principle of this approach when applied to OPC for
single HPV target-detection was reported recently [22]. The present
study builds on this work through the evaluation of a ddPCR approach
to measure VL of two HPV gene targets: E6 and L1, within a well
characterised cohort of OPC cases diagnosed in Scotland on which
clinical and survival outcomes are known. Our overarching aim is to
determine the utility of HPV viral load measurement for the risk-stra-
tification of OPC
2. Methods
2.1. Dimensions of original, parent OPC cohort
We focussed on a subsample of an OPC cohort from Scotland
(n=235). Full details of the original cohort are available in Wakeham
et al. 2019 [23]. In brief, patients with OPC diagnosed in the West of
Scotland between April 2013 and December 2015 had PCR-based HPV
typing, performed in a central reference laboratory in Scotland. The
original PCR-based assay targeted L1 DNA and incorporated genotyping
using luminex technology for 24 HPV types including all established
high-risk HPV types. HPV positivity using this technology is associated
with improved clinical outcomes; as described in Wakeham et al.
(2019) and concordance of the assay with p16INK4a staining is be-
tween 80–90 % [2]. Of the technically valid cases (n=229), 136 were
HPV positive and 130/136 were positive for HPV 16.
2.2. Sample(s) used for VL analysis
An aliquot of the original nucleic acid extraction stored at −80 °C,
was obtained. Given the dominance of HPV 16 in OPC generally, in-
cluding the present cohort, HPV 16-specific ddPCR protocols were
generated. 113 HPV 16 positive samples were available for the ddPCR
after exclusion for limiting volume or incomplete clinical data. Of these,
93 and 82 tested positive for L1 and E6 respectively and were the focus
of subsequent analysis. Sex, age, deprivation (represented as quintiles;
1=most deprived, 5 least deprived), smoking (ever/never), alcohol
consumption (heavy vs not), TMN stage, ICON-S stage and treatment-
type were recorded as per Wakeham et al. 2019 [23]. Study permissions
were through NHS Greater Glasgow and Clyde research office, the
clinical effectiveness team and a data sharing agreement with the West
of Scotland Cancer network.
2.3. ddPCR methodology and optimisation
ddPCR was carried out to conform to the MIQE guidelines for
ddPCR [24,25]. Copy number variant (CNV) analysis was used to de-
termine average HPV16 VL/cell. ddPCR assays were set up as duplexes
with the cellular RPP30 control probe primer set, supplied as standard
for ddPCR (BioRad, UK), and either custom-designed HPV16 L1-specific
primers and probe sets (HPV16 L1 Forward Primer 5′-GCCTCCTGTCC
CAGTATCTAA-3′, HPV16L1 Reverse Primer 5′-GGATGTCCAACTGCAA
GTAGTC-3′, HPV16L1 Probe 5′-TGCGTGCAACATATTCATCCGTGC-3′)
[26] or HPV16 E6-specific primers and probe sets (E6 Forward Primer
5′-CAATGTTTCAGGACCCACAG-3′, E6 Reverse Primer 5′-CTGTTGCTT
GCAGTACACACATTC-3′, E6 Probe 5′−CCACAGTTATGCACAGAGC
TGC-3′) [27]. For L1 and E6 probes the reporter dye was FAM and the
dark quencher was BHQ1 (IDT, Belgium). Primers and probes were
designed using IDT’s Primer Quest Tool (https://eu.idtdna.com/
PrimerQuest/Home/Index). The probe/primer sets were optimised
using a temperature gradient exactly as recommended in the Bio-Rad
ddPCR manual. The endogenous control assay kit; Human RPP30 (re-
porter dye HEX) (Bio-Rad, UK) was included in every ddPCR reaction as
a copy number reference, i.e. each ddPCR was a duplex reaction. All
reaction runs contained negative control wells in triplicate. In-reaction
digestion of the DNA with restriction enzymes was performed to en-
hance the partitioning of DNA into droplets. We confirmed that the
restriction enzymes selected for this (EcoRI and HindIII), would not cut
within any of the viral or control target sequences. Primer and probe
concentrations were optimised by titration. Reaction mixes were set up
using ddPCR Supermix for Probes without dUTP (Bio-Rad), 0.7 μL of the
RPP30 endogenous control assay, HPV16 L1 or E6 specific primers and
probes at 300 nM and 200 nM (final concentration) respectively,
10–100 ng of template DNA and 1 μL of restriction digest mix (con-
sisting of 4 U of both EcoRI and HindIII in 1x NEB Cutsmart buffer (NEB,
UK)). Reactions were mixed with Droplet Generation Oil on DG8 car-
tridges in the QX200 droplet generator (Bio-Rad) to generate droplets.
Thermal cycling conditions were: 95 °C for 10min followed by
40× 94 °C for 30 s and 60 °C for 1min prior to final extension at 98 °C
for 10min. Post amplification, droplets were analysed on a QX200
Droplet Reader (Bio-Rad) and output data files were analysed using
QuantaSoft analysis software v1.7.4 (Bio-Rad).
2.4. Definition of low and high VL
The individual viral loads were ranked from smallest to largest and
separated using tertiles. A priori, the analysis planned to compare viral
load in tertiles (low, medium and high) but low numbers of deaths in
the medium and high viral load groups meant that analysis was per-
formed for low VL(viral load in the lowest third) vs a combined
medium/high VL category (viral load in the upper two-thirds); this was
performed for both L1 and E6. The VL threshold(s) for “medium/high”
E6 VL and L1 VL were>8.68 and> 5.57 viral gene copies per cell
respectively. Samples with VL lower than this were classed as having a
low VL.
2.5. E6 and L1 VL and clinical outcome
Analysis was performed on the cases which had ddPCR results
(n= 93 for L1 and n= 82 for E6). Kaplan Meier plots were constructed
for overall and progression free survival, stratified according to the OPC
cases having a low or medium/high VL. In addition, hazard to death
and hazard to death or recurrence were assessed and related to low or
medium/high VL status using Cox’s regression with Firth's penalised
likelihood given the small denominators. Follow up data were censored
as of November 2016. Univariate and adjusted results are presented
with adjustments made for sex, age, deprivation, smoking, alcohol in-
take, TMN stage, ICON stage. Type of treatment was not included in the
model given its high association with stage.
2.6. Ratios of E6 and L1 VL and clinical outcome
The association(s) between E6/L1 ratio and the demographic and
clinical variables were assessed with significance determined using the
Fishers exact test. Further, we modelled the association between the
distance of the E6/L1 ratio to 1 and the variables using a regression
model (to avoid imposing an “arbitrary” cut off). As the effect may have
been different for E6/L1 > 1 vs<1, tests for interaction were per-
formed to determine whether they could be included with the same
model. All statistical analyses were performed in R version 3.6.1.
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3. Results
3.1. Characteristics of cohort assessed for VL
Demographic and clinical variables of the cohort are presented in
Table 1 in addition to VL status separated as “low”, “medium” or
“high”. The cohort contained 75 males and 18 females with an average
age of 57 (interquartile range of 52−66). All were squamous cell car-
cinomas and most cases were from more deprived areas; 50/93 patients
were SIMD 1 and 2. In relation to smoking and alcohol, 53 had “ever”
smoked and 19 were heavy drinkers. A total of 84 cases were TMN 3 or
above and most, (56/93), received chemo-radiotherapy as treatment.
3.2. VL and impact on clinical outcomes (L1)
All original data files for this study have been uploaded to the
University of Glasgow’s open access data sharing platform “Enlighten”
(http://researchdata.gla.ac.uk/) The DOI for accession to this data is
https://doi.org/10.5525/gla.researchdata.1023
Samples were analysed singly and any assay generating less than
10,000 droplets was discounted from analysis. Raw data for the average
HPV16 VL per cell as deduced from ddPCR experiments are presented
in Supplementary Table 3. This shows the VL (based on either the L1 or
E6 DNA targets) calculated relative to the endogenous RRP30 cellular
gene internal control, which is known to have two copies per cell. A
threshold is set on the QuantaSoft analysis software (either auto-
matically or manually as required http://www.bio-rad.com/webroot/
web/pdf/lsr/literature/Bulletin_6407.pdf) and from this, the number of
positive and negative droplets for both gene targets in each patient
sample is measured. The software then fits the positive droplets to a
Poisson algorithm to determine the target DNA concentrations. L1 VL
ranged from 0.0011–304 copies of HPV L1 gene per cell with a mean of
30.9 L1 copies. Those who died from OPC had a median L1 VL of 5.21
(IQR 0.23–18.15); while those still alive had a median L1 VL of 16.3
(IQR 4.13–33.65). Table 2 shows overall survival stratified by the
clinical and demographic variables described in Table 1 in addition to
viral load defined as medium/high (treated as a composite) or low.
Medium/high viral load was associated with improved overall survival
in the univariate analysis with a hazard ratio of 0.3 (95 % CI
0.11−0.84), p= 0.02. Variables associated with a worse overall sur-
vival were high alcohol consumption; HR 4.94 (95 % CI 1.7−14.39)
p < 0.01, more advanced stage and treatment modality. Similar ob-
servations were noted when progression free survival was used as an
outcome (Supplementary data 1). Fig. 1 shows overall survival and
progression free survival according to the binary VL categories.
In the adjusted analysis no individual variable, including viral load,
influenced overall survival other than high alcohol consumption; HR
3.6 (95 % CI 0.98−15.22) – although the confidence interval spanned
1. Alcohol consumption was also associated with a significantly worse
progression free survival; HR 5.48 (95 % CI 1.56–19.22) in the adjusted
analysis (supplementary Table 1).
3.3. VL and impact on clinical outcomes (E6)
E6 VL ranged from 0.0012–356 copies of HPV E6 gene per cell.
Mean viral load was 37.9 E6 gene copies per cell and those who died
from OPC had a E6 VL of 12.19 (IQR 6.65–39.25), while those still alive
had a median E6 VL of 15.69 (IQR 6.04–41.81).
Medium/high viral load was weakly associated with longer overall
survival and progression free survival although the relationship was not
as strong as that observed for L1 (Fig. 2). In the univariate analyses,
medium/high E6 VL was associated with a slightly higher overall sur-
vival although this was not significant; HR 0.76 (95 %CI 0.21−2.68)
p=0.67 (Table 3, Fig. 2). High alcohol intake was associated with
worse overall survival; HR 4.31 (95 %CI 1.18−15.67) p=0.03, as was
treatment type. These observations were unchanged when progression
free survival was assessed (Supplementary Table 2).
3.4. L1 v s E6 ratio
All viral genes in an HPV genome have an expected copy number of
one. Comparison of VL measured by L1 versus E6 gene copy number
revealed a small deviance from “copy=one” in almost all cases.
However, in 19 cases out of 82 positive for E6, there was almost a one
log range of values (0.262–2.27 copies of E6/L1) (Fig. 3). We modelled
the distance of E6/L1 to 1 against demographic and clinical variables;
none of the demographic or clinical variables were significantly asso-
ciated with the distance of E6/L1 to 1.
4. Discussion
We have demonstrated that ddPCR is an accurate and rapid method
for determining HPV VL in OPC patients, consistent with previous
studies in smaller cohorts [28,29]. The VL detected with both E6 and L1
genes displayed a wide range but was much more restricted than the
103 to 107 range reported for 48 OPC patients [12] or 1-> 900 copies
in 45 clinical samples, [29], which both detected L1 gene copy num-
bers.
The ddPCR analysis indicated that a higher L1 VL was associated
with better clinical outcomes. One explanation is that cancers with a
Table 1
Table 1: Demographic & clinical characteristics of the study cohort, including
L1 and E6 viral load.
Variable Level n (%) (Total= 93)
Sex Female 18(19.4)
Male 75(80.6)
Age < 50 14(15.1)
50−59 42(45.2)
60−69 20(21.5)
70 and over 17(18.3)
median (IQR) 57 (52−66)




5: least deprived 15(16.1)
Missing 1(1.1)
Smoking status No 38(40.9)
Yes 53(57)
Missing 2(2.2)
Alcohol status No 69(74.2)
Yes 19(20.4)
Missing 5(5.4)
















L1 viral load low (< =5.57) 31(33.3)
medium (5.57,25.63] 31(33.3)
high (> 25.63) 31(33.3)
E6 viral load low (< =8.68) 28(30.1)
medium (8.68,28.51] 27(29)
high (> 28.51) 27(29)
missing 11(11.8)
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higher VL are virus “driven” - whereas those with lower VLs may re-
present cancers where other drivers are responsible for the cancer due
to impairment of viral function through integration and/or epigenetic
mechanisms. Notably, we detected very low levels indeed of L1 with
some as low as 0.001 copies per cell. Although such samples tested
positive for HPV16 in the original HPV PCR/genotyping test, we accept
that the presence of the virus might not drive tumorigenesis in these
cases and that some tumours in the “low VL” group could be treated as
functionally HPV-negative. We did not test cancers for p16INK4a or E6
RT-PCR or perform in-situ hybridisation for E6/E7 sequences, which
can indicate transcriptional activity of virus. This would be of interest
for future work and could better clarify the relevance and activity of the
virus of the “low VL” group [[30]].
It is known that the mutational burden of HPV-positive OPC is lower
than HPV negative cancer; making it amenable to non-surgical treat-
ment options [7]. This may be because the majority of OPCs retain viral
episomes and there is a lack of insertional mutagenesis of cellular genes
due to integration [31]. Therefore, the association of a higher VL with
better outcome could be that multiple viral episomes might allow full
virus gene expression, particularly of the highly immunogenic L1 pro-
tein. Theoretically, this would allow for greater antigen presentation
and immune checks, particularly in the tonsils, which are lymphoid
tissue.
HPV genome status in OPC tumours can be episomal or integrated
or exist as virus-human episomes or integrants [[32]. While the re-
lationship between integration status and clinical outcome is not fully
understood, only low copy numbers have been detected in cases with
integrated HPV genomes [32]. Our samples had a mean viral load of
30.9 (L1) or 37.9 (E6), and VL with L1 detection was similar to VL with
E6 detection, suggesting the majority of samples had mostly episomal
genomes, but this requires confirmation. A surprising finding was that
in the majority of samples, the ratio of E6 to L1 was not equal to one
and some had greater numbers of E6 vs L1 copies; this may be explained
by amplification of E6/E7 genes either in episomal or integrated viral
genomes due to recombination events. Conversely, the samples which
had more L1 than E6 copies may reflect the presence of full-length
genomes alongside partially deleted viral genomes missing the E6 gene.
We could not demonstrate a relationship between L1:E6 ratios and
clinical/demographic variables or outcomes, but this may be an artefact
of the small number of cases. Viral activity in OPCs, including level of
HPV gene expression is likely to provide further insight on clinical
outcomes. While sequencing is required to address this question, our
Table 3
Overall survival stratified by clinical variables,demographic variables and E6 viral load. HR derived using cox regression apart from SIMD and treatment which
derived using cox regression with Firth's penalized likelihood, due to small counts of events. 4 patients were removed in the adjusted model due to missing in SIMD/
smoking/alcohol. Adjusted for ICON and TMN stage separately. For TMN stage, 1-3 combines the levels 1 (2 cases, 0 died),2 (3 cases, 1 died) and 3 (10 cases, 0 died)












Rate per 100 person
years (95 % CI)
univariate HR (95
% CI)
p value adjusted HR (95 % CI) p value adjusted HR (95 % CI) p value
E6 Low 28 4 58.3 6.9(1.9−17.6) 1 1 1
Medium/
high
54 6 115.6 5.2(1.9−11.3) 0.76(0.21−2.68) 0.67 0.5(0.06−2.54) 0.42 0.26(0.02−1.71) 0.17
Sex Female 16 3 34.3 8.7(1.8−25.5) 1 1 1
Male 66 7 139.6 5(2−10.3) 0.57(0.15−2.21) 0.42 0.33(0.03−2.15) 0.25 0.32(0.03−2.09) 0.24
Age < 50 14 2 29.5 6.8(0.8−24.5) 1 1 1
50−59 41 3 89.2 3.4(0.7−9.8) 0.47(0.08−2.82) 0.41 0.24(0.02−2.18) 0.2 0.11(0.01−1.13) 0.06
60−69 15 2 29.2 6.9(0.8−24.8) 0.93(0.13−6.65) 0.94 0.93(0.06−11.59) 0.96 0.38(0.03−3.75) 0.41
70 and
over
12 3 26 11.6(2.4−33.8) 1.66(0.28−9.94) 0.58 2.5(0.32−27.36) 0.38 2.91(0.33−53.99) 0.35
SIMD 1: most
deprived
23 3 46.5 6.4(1.3−18.8) 1 1 1
2 18 2 37.1 5.4(0.7−19.5) 0.9(0.15−4.64) 0.9 0.96(0.13−5.48) 0.96 0.95(0.12−6.59) 0.96
3 11 3 22.5 13.3(2.7−38.9) 2.01(0.42−9.47) 0.36 4.49(0.65−44.58) 0.13 6.07(0.65−95.37) 0.12
4 14 2 30.9 6.5(0.8−23.4) 1.06(0.18−5.47) 0.94 1.96(0.23−19.18) 0.53 3.36(0.45−28.64) 0.22
5: least
deprived




No 36 2 77.5 2.6(0.3−9.3) 1 1 1




No 65 6 142.2 4.2(1.5−9.2) 1 1 1




1−3 15 1 31.5 3.2(0.1−17.7) 1 1
4a-c 67 9 142.4 6.3(2.9−12) 2.06(0.26−16.23) 0.49 5.22(0.62−135.55) 0.15
ICON
stage
1 9 1 19.7 5.1(0.1−28.2) 1 1
2 51 3 111 2.7(0.6−7.9) 0.52(0.05−4.99) 0.57 0.96(0.11−16.37) 0.98
3−4 22 6 43.1 13.9(5.1−30.3) 2.79(0.34−23.21) 0.34 3.24(0.43−67.01) 0.31
Treatment RT 12 3 23.8 12.6(2.6−36.8) 1
BSC 3 3 1.8 169.2(34.9−494.6) 25.07(4.09−188.2) < 0.01
CRT 54 3 116.6 2.6(0.5−7.5) 0.2(0.04−0.96) 0.05
SCRT 10 0 25.8 0(0−14.3) 0.13(0−1.35) 0.09
SRT 3 1 5.8 17.1(0.4−95.3) 1.97(0.19−12.14) 0.51
In the medium VL group there are 3 deaths with an event rate of 5.3 per 100 person years 95 % CI (1.1–15.4) and in the high group there are also 3 deaths with an
event rate of 5.1 per 100 person years 95 % CI (1.1–14.9).
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data provide further proof of the instability of the HPV genome in OPC.
In the adjusted analysis, VL was not independently associated with
improved outcomes. This is consistent with the fact that OPC is influ-
enced by various behavioural, demographic and clinical factors and
their complex interplay. Consequently, L1 VL may be a proxy of one or
a combination of these but nevertheless represents a tool which can be
applied objectively to ascertain risk-groups within the HPV positive
category. It is also feasible that VL may be used to indicate/inform
treatment options. Trials of therapy in OPC based on HPV status have
generally relied on qualitative tests; it would be of value to include VL
in such studies to determine if it serves as a complimentary biomarker
of disease outcomes [33].
There are limitations to the study – although the sample set was well
annotated it was still relatively small. In addition, we did not impose
Fig. 1. Overall Survival (upper plot) and Progression Free Survival (lower plot) associated with “medium/high” and “low” L1 VL as measured by ddPCR (> 5.57 viral
gene copies per cell=medium/high L1 VL).
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additional tools to determine viral activity & physical state which may
have helped explain the findings, including the relationship between L1
and E6 ratios. Nevertheless, given the increasing burden of OPC
globally and the desire for optimal management strategies - we would
argue that assessment of viral load is worthy of further investigation. To
this end we aim to confirm our findings in a larger patient cohort where
Fig. 2. Overall Survival (upper plot) and Progression Free Survival (lower plot) associated with “medium/high” and “low” E6 VL as measured by ddPCR (> 8.86 viral
gene copies per cell=medium/high E6 VL).
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complimentary biomarkers of viral activity including p16INK4a and
E6/E7 mRNA detection [34] are imposed and where increased power
would allow further categorisation of load beyond binary groups.
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